Market by Therapeutics, Diagnostics, and Country Outlook | Forecast 2022-2028
A study by Triton on Europe’s Alzheimer’s disease therapeutics and
diagnostics market shows that the market will develop with a CAGR of 7.17%
in the forecast duration 2022-2028.
Report scope can be customized per your requirements. Request For Customization
The countries included in this market include:
• France
• The
United Kingdom
• Spain
• Germany
• Italy
• Rest
of Europe
Germany is
expected to witness the fastest growth in the region. The rising
mortality rate from Alzheimer’s disease and government initiatives like
conferences and meetings to raise awareness of the condition are the primary
factors driving the Alzheimer’s disease therapeutics and diagnostics market in
Europe.
Germany has a population of approximately 83 million people,
according to the German Federal Statistical Office’s 2020 report. Among these,
16.2 million people are aged 67 years or older, and by 2040, nearly 21.4
million are expected to constitute this age group. With the increase in the
elderly population in the foreseeable future, the demand for AD therapeutics and
diagnostics is expected to soar. This is because older adults are more likely
to develop neurological conditions like dementia or Alzheimer’s disease.
According to the World Population Ageing 2019 report, 13.93
million people in Italy were aged 65 years or older in 2019, and 16.46 million
people would reach that age by 2030. The Italian government has taken the lead
for the development of efficient pharmaceuticals in the near future due to the
nation’s high geriatric population. According to the National Clinical Trials
Registry (NCT), there are currently roughly 16 active Alzheimer’s disease
clinical trials in various stages of development in Italy. These
developments aid the Alzheimer’s disease therapeutics and diagnostics market
growth.
A structural imaging technique called MRI can provide details
about the location, volume, or shape of the brain tissue. It is better than
other diagnostics methodologies in a number of ways. One of the main benefits
of this technique is its accuracy in detecting extremely minute variations in
soft tissues. Due to these benefits, MRI is frequently used for nervous system
imaging, including for the diagnosis of Alzheimer’s disease.
The report assesses the market based on therapeutics
and diagnostics. Here, the
diagnostics segment comprises magnetic resonance imaging, blood test,
electroencephalography, positron emission tomography, lumbar puncture test,
computed tomography, and other diagnostics.
Some of the distinguished companies in the Alzheimer’s disease
therapeutics and diagnostics market are Sun Pharmaceuticals Industries Ltd,
Cognoptix Inc, Teva Pharmaceutical Industries Ltd, GE Healthcare, Siemens
Healthineers AG, Pfizer Inc, Johnson and Johnson, and Lupin Limited.
Novartis
International AG is a leading pharmaceutical company. It is involved in the
discovery, production, and marketing of generic pharmaceuticals, eye care
products, and medications. It offers Amilomotide and Exelon Patch under its AD
treatment products category. The latter is a prescription medicine to treat
mild, moderate, and severe memory issues associated with Alzheimer’s disease. The
company is headquartered in Basel, Switzerland.
Key deliverables of the report:
· Market CAGR during the forecasting years 2022-2028
· Detailed data highlighting key insights, industry components, and market strategies
· Comprehensive information and estimation of the Alzheimer’s disease therapeutics and diagnostics market revenue growth in Europe and its influence on the parent market
· In-depth study of forthcoming trends in consumer behavioral patterns
· A meticulous analysis of the competitive landscape, vendor scorecard, and Porter’s Five Forces Model
·
A wide-ranging study of factors that will challenge the Europe Alzheimer’s
disease therapeutics and diagnostics market’s growth during the upcoming years
Want to get specific insights? Our team of analysts can customize
this report based on your preferences. Connect with us here.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1. EUROPE
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET - SUMMARY
2. INDUSTRY
OUTLOOK
2.1. TIMELINE
OF ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET
2.2. PHASES
AND STERNNESS OF ALZHEIMER’S DISEASE
2.3. KEY
INSIGHTS
2.3.1. USAGE
OF COMPUTED TOMOGRAPHY FOR THE DIAGNOSIS OF ALZHEIMER’S DISEASE
2.3.2. R&D
INVESTMENTS IN BIOMARKERS FOR EARLY DETECTION OF DEMENTIA
2.3.3. DEMAND
FOR PERSONALIZED MEDICINES
2.4. IMPACT
OF COVID-19 ON THE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET
2.5. PORTER’S
FIVE FORCES ANALYSIS
2.6. MARKET
ATTRACTIVENESS MATRIX
2.7. VENDOR
SCORECARD
2.8. INDUSTRY
COMPONENTS
2.8.1. RESEARCH
& DEVELOPMENT (R & D)
2.8.2. RAW
MATERIALS
2.8.3. MANUFACTURING
2.8.4. DISTRIBUTORS/WHOLESALERS/RETAILERS
2.8.5. END-USER
2.9. KEY
IMPACT ANALYSIS
2.9.1. EFFECTIVENESS
2.9.2. PRICE
2.9.3. SAFETY
2.10. KEY
MARKET STRATEGIES
2.10.1. ACQUISITIONS
2.10.2. PRODUCT
LAUNCHES
2.10.3. CONTRACTS
& AGREEMENTS
2.10.4. INVESTMENTS
& EXPANSIONS
2.11. MARKET
DRIVERS
2.11.1. PREVALENCE
OF ALZHEIMER’S DISEASE
2.11.2. RISE
IN THE ELDERLY POPULATION
2.12. MARKET
CHALLENGES
2.12.1. FAILURE
OF LATE-STAGE DRUGS
2.12.2. STRINGENT
GOVERNMENT REGULATIONS
2.13. MARKET
OPPORTUNITIES
2.13.1. EMERGENCE
OF NEW DIAGNOSTIC TECHNOLOGIES
2.13.2. GROWING
NUMBER OF PIPELINE DRUGS
3. EUROPE
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – BY THERAPEUTICS
3.1. BY
DRUG TYPE
3.1.1. MARKETED
DRUGS
3.1.2. PIPELINE
DRUGS
3.2. BY
DISEASE STAGE
3.2.1. LATE
STAGE: SEVERE AD
3.2.2. EARLY/MIDDLE
STAGE: MILD TO MODERATE AD
3.2.3. PRODROMAL
STAGE
3.3. BY
GENERIC & BRANDED
3.3.1. BRANDED
3.3.2. GENERIC
4. EUROPE
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – BY DIAGNOSTICS
4.1. LUMBAR
PUNCTURE TEST
4.2. POSITRON
EMISSION TOMOGRAPHY
4.3. ELECTROENCEPHALOGRAPHY
4.4. MAGNETIC
RESONANCE IMAGING
4.5. COMPUTED
TOMOGRAPHY
4.6. BLOOD
TEST
4.7. OTHER
DIAGNOSTICS
5. EUROPE
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – COUNTRY OUTLOOK
5.1. UNITED
KINGDOM
5.2. GERMANY
5.3. FRANCE
5.4. ITALY
5.5. SPAIN
5.6. REST
OF EUROPE
6. COMPETITIVE
LANDSCAPE
6.1. BAXTER
INTERNATIONAL INC
6.2. F.
HOFFMANN-LA ROCHE AG
6.3. ALLERGAN
PLC (ACQUIRED BY ABBVIE)
6.4. NOVARTIS
AG
6.5. PFIZER
INC
6.6. SIEMENS
HEALTHINEERS AG
6.7. AMARANTUS
BIOSCIENCE HOLDINGS INC
6.8. EISAI
CO LTD
6.9. ELI
LILLY & COMPANY
6.10. LUPIN
LIMITED
6.11. MERCK
AND CO
6.12. BIOGEN
INC
6.13. COGNOPTIX
INC
6.14. GE
HEALTHCARE
6.15. JOHNSON
AND JOHNSON
6.16. SUN
PHARMACEUTICALS INDUSTRIES LTD
6.17. TEVA
PHARMACEUTICAL INDUSTRIES LTD
6.18. ZYDUS
CADILA
7. METHODOLOGY
& SCOPE
7.1. RESEARCH
SCOPE
7.2. SOURCES
OF DATA
7.3. RESEARCH
METHODOLOGY
TABLE 1: EUROPE
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK,
2022-2028 (IN $ MILLION)
TABLE 2: MARKET
ATTRACTIVENESS MATRIX
TABLE 3: VENDOR
SCORECARD
TABLE 4: KEY STRATEGIC
DEVELOPMENTS
TABLE 5: EUROPE
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS,
2022-2028 (IN $ MILLION)
TABLE 6: EUROPE
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2028 (IN $ MILLION)
TABLE 7: EUROPE
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, 2022-2028 (IN $
MILLION)
TABLE 8: EUROPE
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, 2022-2028
(IN $ MILLION)
TABLE 9: EUROPE
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTICS,
2022-2028 (IN $ MILLION)
EUROPE ALZHEIMER’S
DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $
MILLION)
FIGURE 1: PORTER’S FIVE
FORCES ANALYSIS
FIGURE 2: KEY IMPACT
ANALYSIS
FIGURE 3: TIMELINE OF
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS
FIGURE 4: INDUSTRY
COMPONENTS
FIGURE 5: EUROPE
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS, 2021
& 2028 (IN %)
FIGURE 6: EUROPE
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUG TYPE, 2021 & 2028 (IN %)
FIGURE 7: EUROPE
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY MARKETED DRUGS, 2022-2028 (IN $
MILLION)
FIGURE 8: EUROPE
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY PIPELINE DRUGS, 2022-2028 (IN $
MILLION)
FIGURE 9: EUROPE
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, 2021 & 2028 (IN
%)
FIGURE 10: EUROPE
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY LATE STAGE: SEVERE AD, 2022-2028
(IN $ MILLION)
FIGURE 11: EUROPE
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY EARLY/MIDDLE STAGE: MILD TO
MODERATE AD, 2022-2028 (IN $ MILLION)
FIGURE 12: EUROPE
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY PRODROMAL STAGE, 2022-2028 (IN $
MILLION)
FIGURE 13: EUROPE
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, 2021 &
2028 (IN %)
FIGURE 14: EUROPE
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY BRANDED, 2022-2028 (IN $ MILLION)
FIGURE 15: EUROPE
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC, 2022-2028 (IN $ MILLION)
FIGURE 16: EUROPE
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2021
& 2028 (IN %)
FIGURE 17: EUROPE
ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY LUMBAR PUNCTURE TEST, 2022-2028 (IN
$ MILLION)
FIGURE 18: EUROPE
ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY POSITRON EMISSION TOMOGRAPHY,
2022-2028 (IN $ MILLION)
FIGURE 19: EUROPE
ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY ELECTROENCEPHALOGRAPHY, 2022-2028
(IN $ MILLION)
FIGURE 20: EUROPE
ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY MAGNETIC RESONANCE IMAGING,
2022-2028 (IN $ MILLION)
FIGURE 21: EUROPE
ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY COMPUTED TOMOGRAPHY, 2022-2028 (IN $
MILLION)
FIGURE 22: EUROPE
ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY BLOOD TEST, 2022-2028 (IN $ MILLION)
FIGURE 23: EUROPE
ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY OTHER DIAGNOSTICS, 2022-2028 (IN $
MILLION)
FIGURE 24: EUROPE
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021
& 2028 (IN %)
FIGURE 25: UNITED
KINGDOM ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $
MILLION)
FIGURE 26: GERMANY
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $
MILLION)
FIGURE 27: FRANCE
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $
MILLION)
FIGURE 28: ITALY
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $
MILLION)
FIGURE 29: SPAIN
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $
MILLION)
FIGURE 30: REST OF
EUROPE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $
MILLION)